Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.42 |
| ▸ | GRM5 | P41594 | 9/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17222886 | 0.88 | NAMPT (0.52) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL15077315 | 0.87 | NAMPT (0.48) | NAMPTALDH1A1LMNAMAPTPDK4 | |
| SCHEMBL15053094 | 0.85 | CYP2C9 (0.37) | ALDH1A1MAPTSOS1 | |
| SCHEMBL18326659 | 0.85 | NAMPT (0.49) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL15053093 | 0.85 | CYP2C9 (0.37) | ALDH1A1MAPTSOS1 | |
| SCHEMBL17229879 | 0.84 | GRM1 (0.50) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL2746929 | 0.83 | NAMPT (0.48) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL2909557 | 0.82 | ALDH1A1 (0.59) | NAMPTALDH1A1LMNAMAPTPDK4 | |
| SCHEMBL2634572 | 0.82 | PDK4 (0.53) | NAMPTALDH1A1LMNAMAPTPDK4 | |
| SCHEMBL30112463 | 0.82 | PDK4 (0.53) | NAMPTALDH1A1LMNAMAPTPDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864289-B1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTED AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | CB THERAPEUTICS INC (KY) | 2018-04-11 | — | — | EP | disclosed |
| US-9840477-B2 | Cyclopropanecarboxamido-substituted aromatic compounds as anti-tumor agents | CB THERAPEUTICS INC. (KY) | 2017-12-12 | — | — | US | disclosed |
| US-9840477-B2 | Cyclopropanecarboxamido-substituted aromatic compounds as anti-tumor agents | CB THERAPEUTICS INC. (KY) | 2017-12-12 | — | — | US | disclosed |
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | APOLLOMICS INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | APOLLOMICS INC. | 2016-09-29 | — | — | US | disclosed |
| US-9359338-B2 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents | CROWN BIOSCIENCE INC. (TAIWAN) (TW) | 2016-06-07 | — | — | US | disclosed |
| US-9359338-B2 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents | CROWN BIOSCIENCE INC. (TAIWAN) (TW) | 2016-06-07 | — | — | US | disclosed |
| US-20150197511-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | APOLLOMICS INC. | 2015-07-16 | — | — | US | disclosed |
| US-20150197511-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | APOLLOMICS INC. | 2015-07-16 | — | — | US | disclosed |
| EP-2864289-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | Crown Bioscience Inc. (Taiwan) (CN) | 2015-04-29 | — | — | EP | disclosed |
| WO-2014000418-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | CROWN BIOSCIENCE INC. (TAICANG) (CN) | 2014-01-03 | — | — | WO | disclosed |
| EP-2616443-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | BRAF, RAF1, ARAF | NAMPT 2787/4885ALDH1A1 4211/4885LMNA 3911/4885 |
| US-20150197511-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | BRAF, ARAF, RAF1 | NAMPT 2384/4885ALDH1A1 3903/4885LMNA 3662/4885 |
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | NAMPT 3954/4885ALDH1A1 1886/4885LMNA 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.